Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
Company Presentation January 2013 - Epigenomics AG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
R&D Capabilities and Future Product Opportunities<br />
Biomarker discovery,<br />
confirmation and selection<br />
� <strong>Epigenomics</strong>’ core capabilities and proprietary technology enabling epigenetic<br />
biomarker discovery and IVD development<br />
� <strong>Epigenomics</strong>’ DNA methylation biomarkers have broad IP protection: 70 active patent<br />
families and licenses provide extensive protection for markers and methods<br />
� <strong>Epigenomics</strong> has identified and validated over 20 proprietary prognostic, predictive,<br />
response, diagnostic, and screening biomarkers in colorectal cancer, lung cancer,<br />
prostate cancer, and bladder cancer<br />
� Internal development is currently focused on Epi proColon®, <strong>Epigenomics</strong> actively<br />
pursues license opportunities for several biomarkers<br />
26 | <strong>January</strong> <strong>2013</strong><br />
•core capabilities<br />
IVD test development,<br />
validation and regulatory<br />
Commercialization
Change language